SCHEMBL3003763

SCHEMBL3003763

CCc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4c(F)c(F)c(F)c(F)c4F)CC3)n2)cc1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.43
ALDH1A1 P00352 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
MAPK1 P28482 3/20 0.42
LMNA P02545 3/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
MAPT P10636 4/20 0.38
USP2 O75604 2/20 0.38
RECQL P46063 1/20 0.38
HSD17B10 Q99714 1/20 0.38
HSD11B1 P28845 1/20 0.37
THRB P10828 1/20 0.37
OGA O60502 1/20 0.36
DNM1L O00429 1/20 0.34
PKM P14618 2/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3003710 0.92 ALDH1A1 (0.41) SMN1; SMN2ALDH1A1L3MBTL1MAPK1LMNA
SCHEMBL3002005 0.92 ALDH1A1 (0.43) SMN1; SMN2ALDH1A1L3MBTL1MAPK1LMNA
SCHEMBL3018745 0.90 PKM (0.47) SMN1; SMN2ALDH1A1L3MBTL1MAPK1LMNA
SCHEMBL3013754 0.89 SMN1; SMN2 (0.43) SMN1; SMN2ALDH1A1L3MBTL1MAPK1LMNA
SCHEMBL3014136 0.89 KMT2A (0.46) SMN1; SMN2ALDH1A1L3MBTL1MAPK1LMNA
SCHEMBL3018873 0.89 MEN1 (0.41) SMN1; SMN2ALDH1A1L3MBTL1MAPK1LMNA
SCHEMBL3012931 0.89 MAPT (0.46) SMN1; SMN2ALDH1A1L3MBTL1MAPK1LMNA
SCHEMBL3020191 0.87 ALDH1A1 (0.41) SMN1; SMN2ALDH1A1L3MBTL1MAPK1LMNA
SCHEMBL3023130 0.86 ALDH1A1 (0.60) SMN1; SMN2ALDH1A1L3MBTL1MAPK1LMNA
SCHEMBL3002027 0.86 ALDH1A1 (0.42) SMN1; SMN2ALDH1A1L3MBTL1MAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885ALDH1A1 3510/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.